Mansfield Advisors considers the evolving roles of CDMOs - Investors in Healthcare

Summary

The article discusses the evolving role of Contract Manufacturing Organizations (CDMOs) in biopharma, highlighting trends like strategic partnerships and end-to-end service offerings. It reflects the growing demand for outsourced drug manufacturing and how companies like Samsung Biologics and Catalent are expanding capacity. The biopharmaceutical industry's shift to outsourcing, particularly in the United States, is creating investment opportunities within the pharmaceutical supply chain. The tags indicate the article's relevance to the broader context of R&D, outsourcing, and strategic partnerships within the pharmaceutical industry, with specific references to industry leaders and market dynamics.